Distribution of delirium motor subtypes in the intensive care unit: a systematic scoping review

Table 4 Secondary outcomes

Delirium motor subtype	Studies reporting on outcome (n)	No. of patients with outcome (n)	Pooled mean/proportion	95% CI
Delirium duration
Hypoactive	26	1589	2.4 days	1.9–2.8
Hyperactive	25	709	2.2 days	1.7–2.7
Mixed	23	1591	3.6 days	2.6–4.5
ICU length of stay
Hypoactive	25	1707	8.4 days	6.4–10.5
Hyperactive	22	541	6.9 days	5.1–8.8
Mixed	22	1513	10.3 days	7.7–12.9
Hospital length of stay
Hypoactive	19	1596	20.0 days	15.8–24.2
Hyperactive	16	545	18.5 days	14.2–22.8
Mixed	17	1670	25.1 days	18.3–31.9
ICU mortality
Hypoactive	12	779	27.9%	17.5–38.3
Hyperactive	9	313	21.8%	9.4–34.2
Mixed	9	685	30.0%	14.1–45.9
Hospital mortality
Hypoactive	4	305	27.2%	10.1–44.3
Hyperactive	3	106	30.1%	4.8–57.1
Mixed	4	305	32.8%	15.3–50.4
Delirium-targeted pharmacological strategy*
Hypoactive	7	358	38.8%	17.0–60.7
Hyperactive	7	258	63.7%	39.8–87.5
Mixed	7	479	58.3%	32.4–84.3
Administration of antipsychotics**
Hypoactive	9	885	39.4%	16.0–62.9
Hyperactive	8	321	56.2%	31.6–80.8
Mixed	9	1073	58.5%	34.2–82.9
Administration of α2-agonists**
Hypoactive	7	214	22.1%	10.1–34.1
Hyperactive	7	188	33.4%	13.5–53.3
Mixed	7	275	53.7%	25.4–82.0
Administration of benzodiazepines**
Hypoactive	7	237	31.9%	16.5–47.2
Hyperactive	7	194	28.0%	21.8–34.1
Mixed	7	251	54.1%	29.6–78.7
Administration of propofol**
Hypoactive	6	188	53.1%	31.0–75.2
Hyperactive	6	164	56.0%	28.1–83.8
Mixed	6	242	67.7%	39.3–96.1

^*Patients intervened with a delirium-targeted pharmacological treatment strategy during ICU stay
^**Patients receiving administration of this specific agents while in the ICU with no limits to indication

ISSN: 1364-8535